A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

University of California, San Francisco

Overview

This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Frontotemporal Lobar Degeneration

Interventions

MemantineDRUG

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Neary et al. Criteria for Frontotemporal Lobar Degeneration * Age 40 -80 * CDR \< 3 or MMSE \> 15 * English Speaking * Study Partner Exclusion Criteria: * Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.